The powerful government-pharmaceutical industry partnership that has been foisting human papillomavirus (HPV) vaccination on girls and boys around the world since 2006 now has working-age adults within its sights. Mercks Gardasil 9 received U.S. Food and Drug Administration (FDA) approval for expanded use in the 27-45 age group in late 2018, and there are signs that a campaign is afoot to achieve the same end result in other countries. HPV vaccines have been linked to over 100,000 reported adverse events globally, including disabling autoimmune conditions and deaths, but officials seem unconcerned. Merck set the tone for the truth-stretching claim that HPV vaccine risks are negligible when it conducted its initial clinical trials for Gardasil and dismissed as irrelevant the serious medical conditions that arosewithin seven monthsin half of all participants who received the vaccine.